Groowe Groowe / Newsroom / LLY
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

LLY News

Eli Lilly & Co.

Ozempatch: Do Herbal Weight Loss Patches Actually Work? 2026 Consumer Analysis as GLP-1 Patch Ads Surge During Resolution Season

globenewswire.com
NVO LLY

Best Weight Loss Pills for 2026? FDA Approves First Oral GLP-1 as Patients Evaluate Wegovy, Zepbound, and Telehealth Access Pathways

globenewswire.com
NVO LLY

Capital Square Launches New Active Living DST Offering in Richmond's Short Pump Submarket

prnewswire.com
LLY

Best Peptides for Weight Loss 2026: Industry Analysis Examines Compounded GLP-1 Telehealth Access and Pricing Transparency

globenewswire.com
NVO LLY

GLP-1 Agonists (Ozempic, Wegovy, Mounjaro) Market - Global Forecast to 2033: Growing Shift of Weekly Injectables Toward Orals and Multi-Agonists - ResearchAndMarkets.com

businesswire.com
LLY NVO

ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly USA - English USA - English APAC - English

prnewswire.com
LLY

Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies

prnewswire.com
LLY

Obesity Medicine Association Releases Position Statement: A New Era for Medicare & Medicaid Obesity Medication Coverage Ready to Announce with Confidence?

newsfilecorp.com
LLY NVO

GLP-1 Agonists (Ozempic, Wegovy, Mounjaro) Market - Global Forecast to 2033: With the Semaglutide Patent Expiring in 2026 Onwards, the Biosimilars Market is Expected to Grow Significantly

globenewswire.com
LLY

FNB Harvest annonce Distributions réinvesties annuelles estimées révisées pour les FNB Harvest d'actions à revenu élevé pour 2025

businesswire.com
LLY AMZN MSFT NVDA COIN PLTR TSLA META AMD AVGO COST GOOGL NFLX AAPL SOFI